Fibrocell Science Inc (NASDAQ:FCSC) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 836,500 shares, a decrease of 9.1% from the May 30th total of 920,400 shares. Approximately 10.3% of the shares of the company are short sold. Based on an average daily volume of 712,100 shares, the days-to-cover ratio is presently 1.2 days.
Several equities analysts have recently commented on FCSC shares. HC Wainwright upped their target price on Largo Resources from C$5.10 to C$5.20 in a report on Thursday, March 28th. Zacks Investment Research raised DLH from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine raised Zumiez from a “sell” rating to a “hold” rating in a report on Saturday, June 22nd.
An institutional investor recently bought a new position in Fibrocell Science stock. Apis Capital Advisors LLC acquired a new position in Fibrocell Science Inc (NASDAQ:FCSC) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $48,000. Apis Capital Advisors LLC owned approximately 0.26% of Fibrocell Science at the end of the most recent reporting period. 28.04% of the stock is currently owned by institutional investors and hedge funds.
FCSC stock traded up $0.01 on Friday, reaching $1.85. The company’s stock had a trading volume of 29,155 shares, compared to its average volume of 37,589. Fibrocell Science has a 52 week low of $1.45 and a 52 week high of $3.28. The company has a market capitalization of $17.95 million, a P/E ratio of -1.28 and a beta of 1.63. The business has a fifty day simple moving average of $1.91. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.59 and a quick ratio of 3.59.
Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.07). Research analysts anticipate that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Read More: Why do commodities matter?
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.